-
公开(公告)号：US20210115099A1
公开(公告)日：2021-04-22
申请号：US16347384
申请日：2017-11-07
Applicant: IMMUNOCORE LIMITED
Inventor： Alex POWLESLAND , Chandramouli CHILLAKURI , Dhaval SANGANI , Graham HOOD , Elena GALFRE
IPC: C07K14/47 , C07K14/74 , C07K14/725 , G01N33/574
Abstract: The present invention provides a peptide comprising, consisting essentially of or consisting of (i) the amino acid sequence KMPEAGEEQPQV (SEQ ID NO: 1); (ii) the amino acid sequence ISQTPGINL (SEQ ID NO: 2); or (iii) the amino acid sequence of SEQ ID NO: 1 or 2 with the exception of 1, 2 or 3 amino acid substitutions and/or 1, 2 or 3 amino acid insertions, and/or 1, 2 or 3 amino acid deletions, wherein the peptide forms a complex with a Major Histocompatibility Complex (MHC) molecule. Also provided are a complex of the peptide a Major Histocompatibility Complex (MHC) molecule, a nucleic acid molecule comprising a nucleic acid sequence encoding the peptide, a vector comprising such a nucleic acid sequence, a cell comprising such a vector and a binding moiety that binds the peptide.
-
公开(公告)号：US20180334476A1
公开(公告)日：2018-11-22
申请号：US15777180
申请日：2016-11-23
Applicant: IMMUNOCORE LIMITED , ADAPTIMMUNE LIMITED
Inventor： Alex POWLESLAND , Fiona CHESTER , Pietro DELLACRISTINA , Chandramouli CHILLAKURI , Dhaval SANGANI , Graham HOOD , Alfred LIM
CPC classification number: C07K7/06 , C07K7/08 , C07K14/4748 , C07K14/70539
Abstract: The present invention relates to novel peptides derived from Cancer/testis antigen family 45 member A1 (CT45A1), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC molecules. Also provided by the present invention are binding moieties that bind to the peptides and/or complexes of the invention. Such moieties are useful for the development of immunotherapeutic reagents for the treatment of diseases such as cancer.
-
公开(公告)号：US20210322528A1
公开(公告)日：2021-10-21
申请号：US17243932
申请日：2021-04-29
Applicant: IMMUNOCORE LIMITED , ADAPTIMMUNE LIMITED
Inventor： Alex POWLESLAND , Victoria Arena DE SOUZA , Chandramouli CHILLAKURI , Dhaval SANGANI , Graham HOOD , Benjamin OESTRINGER
IPC: A61K39/00 , C07K14/71 , C07K14/725 , A61K47/68 , A61P35/00
Abstract: The present invention relates to novel peptides derived from Neuropeptide S Receptor (NPSR1), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC molecules. Also provided by the present invention are binding moieties that bind to the peptides and/or complexes of the invention. Such moieties are useful for the development of immunotherapeutic reagents for the treatment of diseases such as cancer.
-
公开(公告)号：US20180339028A1
公开(公告)日：2018-11-29
申请号：US15777613
申请日：2016-11-23
Applicant: IMMUNOCORE LIMITED , ADAPTIMMUNE LIMITED
Inventor： Alex POWLESLAND , Chandramouli CHILLAKURI , Dhaval SANGANI , Graham HOOD , Benjamin OESTRINGER , Pietro DELLACRISTINA
Abstract: The present invention relates to novel peptides derived from Prostate specific antigen (KLK3), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC molecules. Also provided by the present invention are binding moieties that bind to the peptides and/or complexes of the invention. Such moieties are useful for the development of immunotherapeutic reagents for the treatment of diseases such as cancer.
-
公开(公告)号：US20230330181A1
公开(公告)日：2023-10-19
申请号：US18149664
申请日：2023-01-03
Applicant: IMMUNOCORE LIMITED , ADAPTIMMUNE LIMITED
Inventor： Alex POWLESLAND , Chandramouli CHILLAKURI , Dhaval SANGANI , Graham HOOD , Alina POPA
IPC: A61K38/17 , C07K14/47 , A61K39/00 , A61P35/00 , A61K35/17 , A61K38/03 , C07K14/725 , C12N15/62 , C12N15/79
CPC classification number: A61K38/1774 , C07K14/4748 , A61K39/0011 , A61P35/00 , A61K35/17 , A61K38/03 , C07K14/7051 , C12N15/62 , C12N15/79
Abstract: The present invention relates to novel peptides derived from Kita-kyushu lung cancer antigen 1 (CT83), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC molecules. Also provided by the present invention are binding moieties that bind to the peptides and/or complexes of the invention. Such moieties are useful for the development of immunotherapeutic reagents for the treatment of diseases such as cancer.
-
Patent Agency Ranking
公开(公告)号：US20180339027A1
公开(公告)日：2018-11-29
申请号：US15777880
申请日：2016-11-23
Applicant: IMMUNOCORE LIMITED , ADAPTIMMUNE LIMITED
Inventor： Alex POWLESLAND , Victoria Arena DE SOUZA , Chandramouli CHILLAKURI , Dhaval SANGANI , Graham HOOD , Benjamin OESTRINGER
Abstract: The present invention relates to novel peptides derived from Neuropeptide S Receptor (NPSR1), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC molecules. Also provided by the present invention are binding moieties that bind to the peptides and/or complexes of the invention. Such moieties are useful for the development of immunotherapeutic reagents for the treatment of diseases such as cancer.
-
公开(公告)号：US20180326002A1
公开(公告)日：2018-11-15
申请号：US15777153
申请日：2016-11-23
Applicant: IMMUNOCORE LIMITED , ADAPTIMMUNE LIMITED
Inventor： Alex POWLESLAND , Chandramouli CHILLAKURI , Dhaval SANGANI , Graham HOOD , Alina POPA
CPC classification number: A61K38/1774 , A61K35/17 , A61K38/03 , A61K39/0011 , A61P35/00 , C07K14/4748 , C07K14/7051 , C12N15/62 , C12N15/79
Abstract: The present invention relates to novel peptides derived from Kita-kyushu lung cancer antigen (CT83), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC molecules. Also provided by the present invention are binding moieties that bind to the peptides and/or complexes of the invention. Such moieties are useful for the development of immunotherapeutic reagents for the treatment of diseases such as cancer.
-
公开(公告)号：US20240254228A1
公开(公告)日：2024-08-01
申请号：US18405977
申请日：2024-01-05
Applicant: Immunocore Limited
Inventor： Nicole MAI , Arnaud TECHINE , Jakub JAWORSKI , Kate ATKIN , Nathaniel LIDDY , Vijaykumar KARUPPIAH , Ana PEREIRA RIBEIRO , Ana PENAS , Andrew CREESE , Emma GRANT , Stephen HARPER , Chandramouli CHILLAKURI , Eduardo MATEOS-DIAZ , Tamara ALEKSIC , Pedro CUADRADO RODENAS
IPC: C07K16/28 , A61K38/00 , A61P35/00 , C07K14/725
CPC classification number: C07K16/2809 , A61P35/00 , C07K14/7051 , A61K38/00 , C07K2319/30
Abstract: The present invention relates to binding molecules that comprise T cell receptor (TCR) variable domains and which can bind to a PIWIL1 peptide-HLA complex. The invention also relates to the use of such molecules for the treatment of malignant diseases.
-
公开(公告)号：US20240190969A1
公开(公告)日：2024-06-13
申请号：US17771447
申请日：2020-10-21
Applicant: IMMUNOCORE LIMITED
Inventor： Chandramouli CHILLAKURI , Jorge DIAS DO NASCIMENTO , Conor HAYES , James PARKER , Peter JAMES , Ronan O'DWYER , Andrew POOLE
CPC classification number: C07K16/2833 , A61K35/17 , A61P35/00 , C07K16/2809 , A61K2039/505 , C07K2317/565 , C07K2317/567 , C07K2319/74
Abstract: The present invention relates to specific binding molecules, such as T cell receptors (TCRs), that bind the HLA-A*02 restricted peptide KVLEYVIKV (SEQ ID NO: 1) derived from the germline cancer antigen MAGEA1. The specific binding molecules may comprise non-natural mutations within the alpha and/or beta variable domains relative to a native MAGEA1 TCR. The specific binding molecules of the invention are particularly suitable for use as novel immunotherapeutic reagents for the treatment of malignant disease.
-
10.发明公开公开(公告)号：US20230348595A1
公开(公告)日：2023-11-02
申请号：US17998032
申请日：2021-05-04
Applicant: IMMUNOCORE LIMITED
Inventor： Chandramouli CHILLAKURI , Andrew POOLE , Sarah BAILEY
CPC classification number: C07K16/2809 , A61P35/00 , C07K16/2833 , C07K2317/565 , C07K2317/567 , C07K2319/32
Abstract: The present invention relates to specific binding molecules which bind to an HLA-restricted peptide derived from mutant KRAS. Said specific binding molecules may comprise CDR sequences embedded within a framework sequence. The CDRs and framework sequences may correspond to a T cell receptor (TCR) variable domain and may further comprise non-natural mutations relative to a native TCR variable domain. The specific binding molecules of the invention are particularly suitable for use as novel immunotherapeutic reagents for the treatment of cancer.
-
-
-
-
-
-
-
-
-
Search Results
15
records
(took 0.014 seconds)
